Overview
Study of Omalizumab in Moderate to Severe Bronchial Asthma
Status:
Completed
Completed
Trial end date:
2005-05-01
2005-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will evaluate the safety and efficacy of omalizumab up to 16 weeks in adult patients with moderate to severe bronchial asthma.Phase:
Phase 3Details
Lead Sponsor:
NovartisCollaborator:
Daiichi Sankyo Co., Ltd.Treatments:
OmalizumabCriteria
Inclusion Criteria:- Allergic asthma patients
- Inadequately controlled patients
Exclusion Criteria:
- - History of severe anaphylactoid or anaphylactic reactions
- Previous treatment with omalizumab
- History of cancer or cancer
Other protocol-defined exclusion criteria may apply